Line 46: Line 46:
[[Category:Research Chemical]]

Revision as of 20:37, 23 December 2014

Lsz blotter.jpg

LSZ, also known as Lysergic acid 2,4-dimethylazetidide, is a hallucinogenic drug and an analogue of LSD developed by the team led by David E. Nichols at Purdue University. While LSZ has subtly different effects than LSD, it appears to be slightly longer lasting and slightly more potent.


Light 100-150μg
Common 150-300μg
Strong 300μg+


Onset 90-120 minutes
Total 7-10 hours


While LSZ has subtly different effects than LSD, with a slightly shorter duration while also having a longer comeup.

Harm Reduction

While widespread use of LSZ is relatively new and therefore its full impact is unknown, it is likely that it has a similar safety profile to LSD. Refer to LSD and Psychedelic Harm Reduction for more information.


Legal status


Controlled in the United States via the Federal Analog Act but only if it is intended for human consumption.

Top Contributors